Professor Elaine will present a clinical study called SENSITIZE, which explored the effects of dorzagliatin, the global first-in-class drug, glucokinase activator (GKA) at the ADA Annual Scientific Sessions. This study has been initiated by Professor Juliana Chan, an international endocrinologist from the Chinese University of Hong Kong, explored the effects of dorzagliatin on patients with recent onset T2D and glucokinase-maturity-onset diabetes of the young (GCK-MODY or MODY-2).
Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)